Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 1, 1998, Pages 30-37

  Coccaro, Emil F ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUPENTIXOL; HALOPERIDOL; IMIPRAMINE; LITHIUM CARBONATE; LOXAPINE; LOXAPINE SUCCINATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OXAZEPAM; PHENELZINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

AGGRESSION; BORDERLINE STATE; CLINICAL TRIAL; HUMAN; IMPULSIVENESS; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; TREATMENT OUTCOME;

EID: 0031885135     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Klein DF. Psychiatric diagnosis and a typology of clinical drug effects. Psychopharmacology 1968;13:359-386
2. Rifkin A, Quitkin F, Curillo C, et al. Lithium carbonate in emotionally un-stable character disorders. Arch Gen Psychiatry 1972;27:519-523
3. Spitzer RL, Endicott J, Gibbon M. Crossing the border into borderline personality and borderline schizophrenia. Arch Gen Psychiatry 1979;36: 17-24
4. Baron M, Gruen R, Asnis L, et al. Familial transmission of schizotypal and borderline personality disorders. Am J Psychiatry 1985;927-934
5. Zanarini MC, Gunderson JC, Marino MF, et al. DSM-III disorders in the families of borderline outpatients. J Personality Dis 1988;2:292-302
6. Schulz PM, Soloff PH, Kelly T, et al. A family history study of borderline subtypes. J Personality Dis 1989;3:217-229
7. Silverman JM, Pinkhan L, Horvath TB, et al. Affective and impulsive personality disorder traits in the relatives of borderline personality disorder. Am J Psychiatry 1991;148:1378-1385
8. Coccaro EF, Siever LJ. Neuropsychopharmacology of personality disorders. In: Bloom F, Kupfer D, eds. Psychopharmacology: Fourth Generation of Progress. New York, NY: Raven Press; 1996:1576-1579
9. Coccaro EF, Siever LJ, Klar H, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46:587-599
10. Siever LJ, Trestman RL, Coccaro EF, et al. The growth hormone response to clonidine in acute and remitted depressed male patients. Neuropsychopharmacology 1992;6:165-177
11. Coccaro EF, Lawrence T, Trestman R et al. Growth hormone responses to intravenous clonidine challenge correlates with behavioral irritability in psychiatric patients and in healthy volunteers. Psychiatry Res 1991;39: 129-139
12. Steinberg BJ, Trestman RL, Siever LJ. The cholinergic and noradrenergic neurotransmitter systems and affective instability in borderline personality disorder. In: Silk KR, ed. Biological and Neurobehavioral Studies in Borderline Personality Disorder. Washington, DC: American Psychiatric Press; 1994:41-62
13. Janowsky DS, Risch CS. Role of acetylcholine mechanisms in the affective disorders. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press: 1987:527-534
14. Siever LJ, Silverman JM, Horvath TB, et al. Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. Arch Gen Psychiatry 1990;47:634-640
15. Siever LJ, Keefe R, Bernstein DP, et al. Eye tracking impairment in clinically identified schizotypal personality disorder patients. Am J Psychiatry 1990;147:740-745
16. Siever LJ, Coursey RD, Alterman IS, et al. Impaired smooth-pursuit eye movement: vulnerability marker for schizotypal personality disorder in a normal volunteer population. Am J Psychiatry 1984;141:1560-1566
17. Siever LJ, Amin F, Coccaro EF, et al. Plasma homovanillic acid in schizotypal personality disorder. Am J Psychiatry 1991;148:1246-1248
18. Siever LJ, Amin F, Coccaro EF, et al. Cerebrospinal fluid homovanillic acid in schizotypal personality disorder. Am J Psychiatry 1993;150:149-151
19. Pickar D, Labarca R, Linnoila M, et al. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 1984;225:954-957
20. Davis KL, Davidson M, Mohs RC, et al. Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science 1985;227: 1601-1602
21. Vilkin MI. Comparative chemotherapeutic trial in treatment of chronic borderline patients. Am J Psychiatry 1964;120:1004
22. Hedberg DC, Hauch JH, Glueck BC. Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry 1971;127: 1141-1146
23. Reyntjens AM. A series of multicentric pilot trials with pimozide in psychiatric practice, I: pimozide in the treatment of personality disorders. Acta Psychiatr Belg 1972;72:653-661
24. Brinkley JR, Beitman BD, Friedel RO. Low-dose neuroleptic regimens in the treatment of borderline patients. Arch Gen Psychiatry 1979;36:319-326
25. Hymowitz P, Frances AJ, Jacobsberg LB, et al. Neuroleptic treatment of schizotypal personality disorder. Compr Psychiatry 1986;27:267-271
26. Teicher MH, Glod CA, Aaronson ST, et al. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989;25:535-549
27. Leone NF. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982;43:148-150
28. Serban G, Siegel S. Responses of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984;141: 1455-1458
29. Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene versus placebo. Arch Gen Psychiatry 1986;43:680-686
30. Soloff PH, George A, Nathan RS, et al. Progress in the pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986;43:691-697
31. Soloff PH, George A, Nathan RS, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989;9:238-246
32. Soloff PH, Cornelius JR, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50: 377-385
33. Jensen HV, Anderson J. An open, non-comparative study of amoxapine in borderline disorders. Acta Psychiatr Scand 1989;79:89-93
34. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993;34:402-405
35. Szigethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia [letter]. J Clin Psychopharmacol 1997;17:326-327
36. Khousam HR, Donnelly NJ. Remission of self-mutilation in a patient with borderline personality during risperidone therapy [letter]. J Nerv Ment Dis 1997;195:348-349
37. Montgomery SA. Montgomery D. Pharmacological prevention of suicidal behavior. J Affect Disord 1982;4:291-298
38. Soloff PH, George A, Nathan RS, et al. Paradoxical effects of amitriptyline in borderline patients. Am J Psychiatry 1986;143:1603-1605
39. Links PS, Steiner M, Boiago I, et al. Lithium therapy for borderline patients: preliminary findings. J Personality Dis 1990;4:173-181
40. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trofluroperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45:111-119
41. Parsons B, Quitken FM, McGrath PJ, et al. Phenylzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989;25:524-534
42. Faltus FJ. The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. Am J Psychiatry 1984;141: 802-803
43. Bunney WE, Bunney-Garland BL. Mechanism of action of lithium in affective illness: basic and clinical implications. In: Meltzer HY, ed. Psychopharmacology: Third Generation of Progress. New York. NY: Raven Press; 1987:553-563
44. Sheard M, Marini J, Bridges C, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976;133:1409-1413
45. Klein DF, Greenberg IM. Behavioral effects of diphenylhydantoin in severe psychiatric disorders. Am J Psychiatry 1967;124:847-849
46. Stephens JH, Schaffer JW. A controlled study of the effects of diphenylhydantoin on anxiety, irritability, and anger in neurotic outpatients. Psychopharmacology (Berl) 1970;17:169-181
47. Snyder S, Pitts WM. Electroencephalography of DSM-III borderline personality disorder. Acta Psychiatr Scand 1984;69:129-134
48. Cowdry RW, Pickar D, Davies R. Symptoms and EEG findings in the borderline syndrome. Int J Psychiatry Med 1985-86;15:210-211
49. Cornelius JR, Brenner RP, Soloff PH, et al. EEG abnormalities in borderline personality disorder: specific or nonspecific. Biol Psychiatry 1986;21: 977-980
50. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995;56:506-510
51. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:885-893
52. Cornelius JR, Soloff PH, Perel JM, et al. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990;26:151-154
53. Markovitz PJ, Calabrese JR, Schulz SC, et al. Fluoxetine treatment of borderline and schizotypal personality disorder. Am J Psychiatry 1991;148: 1064-1067
54. Coccaro EF, Astill JL, Herbert J, et al. Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. J Clin Psychopharmacol 1990;10:373-375
55. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994;55: 137-141
56. Fava M, Rosenbaum JF, Pava JA, et al. Anger attacks in unipolar depression, part 1: clinical correlates and response to fluoxetine treatment. Am J Psychiatry 1993;150:1158-1163
57. Markovitz PJ. Pharmacotherapy of impulsivity, aggression and related disorders. In: Stein D, Hollander E, eds. Impulsive Aggression and Disorders of Impulse Control. Sussex, England: J. Wiley; 1995:263-287
58. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clinical Psychopharmacol 1995;15:23-29
59. Coccaro EF, Kavoussi RJ. Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; New Research, May 1995; Miami, Fla. Abstract NR170:101